UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) | June 9, 2006 (June 8, 2006) |
|
NeoPharm, Inc. |
(Exact name of registrant as specified in its charter) |
|
Delaware | 33-90516 | 51-0327886 |
(State or other jurisdiction | (Commission | (IRS Employer |
of incorporation) | File Number) | Identification No.) |
| | |
1850 Lakeside Drive, Waukegan, IL | 60085 |
(Address of principal executive offices) | (Zip Code) |
| | | | |
Registrant’s telephone number, including area code | (847) 887-0800 |
| |
|
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On June 8, 2006, NeoPharm, Inc. (the “Company”) issued a press release announcing that it had been notified by the independent Data Monitoring Committee (iDMC) for the PRECISE Trial involving cintredekin besudotox that the study had reached the criterion for the interim efficacy analysis (160 deaths). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit 99.1 | Press Release dated June 8, 2006 announcing PRECISE Trial had reached criteria for interim efficacy analysis. |
2
SIGNATURE PAGE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NEOPHARM, INC. |
Date: June 9, 2006 | By: | /s/ Lawrence A. Kenyon |
| | Lawrence A. Kenyon, |
| | Chief Financial Officer
(Principal Accounting Officer and
Principal Financial Officer) |
3
